Braidwell LP Sells 207,410 Shares of Krystal Biotech, Inc. $KRYS

Braidwell LP trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 28.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 520,401 shares of the company’s stock after selling 207,410 shares during the quarter. Krystal Biotech comprises about 2.7% of Braidwell LP’s investment portfolio, making the stock its 10th largest holding. Braidwell LP’s holdings in Krystal Biotech were worth $91,866,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sound View Wealth Advisors Group LLC boosted its holdings in Krystal Biotech by 2.9% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock valued at $354,000 after purchasing an additional 56 shares during the period. Bellevue Group AG increased its holdings in shares of Krystal Biotech by 5.0% during the third quarter. Bellevue Group AG now owns 1,312 shares of the company’s stock worth $232,000 after purchasing an additional 62 shares during the period. Bessemer Group Inc. raised its position in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after buying an additional 77 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Krystal Biotech by 1.3% in the third quarter. Arizona State Retirement System now owns 6,397 shares of the company’s stock valued at $1,129,000 after buying an additional 81 shares during the period. Finally, Main Management ETF Advisors LLC grew its position in Krystal Biotech by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock worth $705,000 after buying an additional 84 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $247.26 on Friday. The firm has a market cap of $7.23 billion, a PE ratio of 36.10 and a beta of 0.49. The company has a 50 day simple moving average of $270.50 and a 200 day simple moving average of $222.56. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The company had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. The Goldman Sachs Group boosted their price target on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Guggenheim raised their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Finally, Bank of America increased their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and an average price target of $326.25.

Insider Activity

In other news, Director Daniel Janney sold 11,803 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $275.59, for a total transaction of $3,252,788.77. Following the completion of the sale, the director directly owned 73,293 shares in the company, valued at $20,198,817.87. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dino A. Rossi sold 18,950 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the sale, the director owned 78,691 shares of the company’s stock, valued at approximately $20,570,614.31. The trade was a 19.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 129,164 shares of company stock valued at $34,538,578. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.